Literature DB >> 16395252

CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: the 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis.

F C Berthoux1, P Berthoux, C Mariat, L Thibaudin, A Afiani, M-T Linossier.   

Abstract

The chemokine (CK) receptor 5 (CCR5) is necessary for two adjacent cysteines (CC)-CKs such as Regulated upon Activation Normal T cell Expressed and Secreted, a/o Macrophage Inflammatory Protein 1alpha/beta to mediate their inflammatory properties. The CCR5 gene polymorphism with 32-basepair deletion (d32) leads to receptor inactivation/dysfunction in homo/heterozygous individuals. We have evaluated its role in both initiation and/or progression of primary immunoglobulin A (IgA) nephropathy (IGAN) in a case-control study involving a prospective cohort of 318 IGAN patients and a matched group of 294 controls. Genotyping was performed by a two-specific primers single polymerase chain reaction technique: normal allele (nl) vs d32 allele. The d32 allele frequency was not different in patients (11.0%) vs controls (8.3%), indicating no significant influence on IGAN initiation. Genotype to clinical phenotype correlation demonstrated that progression to renal/patient death was associated with the d32 allele: 18.2% (12 out of 66 with d32) vs 8.3% (21 out of 252); chi(2)=6.73; P=0.017. The Kaplan-Meier survival without renal/patient death was worse in d32-positive patients (log-rank test; P=0.002). The Cox regression analyses confirmed that the nl/nl genotype was a significant and independent protective factor for progression to end-stage renal failure (ESRF)/dialysis: beta/standard error (s.e.)=-3.1; chi(2)=9.5; relative risk=0.31 (95% confidence interval 0.15-0.65); P=0.002. The d32-CCR5 polymorphism played a significant role in the progression of primary IGAN, with the nl/nl genotype being an independent protective factor for late progression towards ESRF/dialysis. These data raise question about the usefulness of systematic CCR5 genotyping in IGAN patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395252     DOI: 10.1038/sj.ki.5000106

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Predicting the risk for dialysis or death in IgA nephropathy.

Authors:  François Berthoux; Hesham Mohey; Blandine Laurent; Christophe Mariat; Aida Afiani; Lise Thibaudin
Journal:  J Am Soc Nephrol       Date:  2011-01-21       Impact factor: 10.121

2.  Association of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: a meta-analysis.

Authors:  Tian-Biao Zhou; Sheng-Sheng Yin; Yuan-Han Qin
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

Review 3.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

4.  Genetic contribution and associated pathophysiology in end-stage renal disease.

Authors:  Suraksha Agrawal; Ss Agarwal; Sita Naik
Journal:  Appl Clin Genet       Date:  2010-08-05

Review 5.  Genetics and immunopathogenesis of IgA nephropathy.

Authors:  Hsin-Hui Yu; Kuan-Hua Chu; Yao-Hsu Yang; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 10.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.